Skip to main content Skip to search Skip to main navigation

PIC/S: What’s planned in terms of GMP?

The Pharmaceutical Inspection Cooperation Scheme (PIC/S) has published its 2022 work plan with the organization’s planned actions for this year. Not only does PIC/S plan to resume its assessments for membership application but also to revise or draft new GMP guidelines.

Revision plans for GMP guidelines in close alignment with the EU include:

  • The finalisation of Annex 1 for sterile manufacturing in alignment with the new EU Annex 1, which is scheduled to be released around September this year. PIC/S is planning to establish an Expert Circle on Sterile Products to train inspectors on the new requirements coming along with the new Annex 1.
  • The revision of the GMP Guide Chapter 1 on Pharmaceutical Quality Systems is planned to be continued/finalized in close co-operation with the EMA’s Inspectors Working Goup (IWG) on GMDP. This is also anticipated for Chapter 4 on Documentation), Annex 11 on Computerised Systems and Annexes 4 and 5 on Veterinary Medicinal Products (VMPs and Immunological VMPs.
  • The publication of concept paper on veterinary specific GMP guidelines in the PIC/S Working group on VMPs.
  • The monitoring of the EU Annex 21 (importation of medicinal products) through the participation of Swissmedic in the Drafting Group. Once finalised, the Committee will need to decide whether to adapt this Annex for PIC/S purposes.

PIC/S GMDP-related guidance documents to be further revised or developed:

  • PE 010-4 PIC/S Guide to Good Practices for the Preparation of Medicinal Products in
  • Healthcare Establishments
  • PI 006-3 Revision of PIC/S Recommendations on Validation Master Plan; Installation
  • and Operational Qualification; Non-Sterile Process Validation; and Cleaning Validation
  • PI 007 Recommendation on Validation of Aseptic Processes
  • PI 011 PIC/S Guidance on Good Practices for Computerised Systems in Regulated GxP Environments
  • PI 013 PIC/S Inspection Report
  • PI 023-2 Aide Mémoire on Inspection of Quality Control Laboratories
  • PI 025 Aide Mémoire on Medicinal Gases
  • PI 030-1 Aide Mémoire on the Inspection of APIs
  • PI 043-2 PIC/S Aide Mémoire on Controlling Cross-Contamination in Shared Facilities
  • PI 050 Aide Mémoire on PIC/S Data Integrity System-Specific Guidance: Chromeleon 7 Chromatography Data Systems and Server/Client Systems
  • PI 019 PIC/S Site Master File for Source Plasma Establishments
  • PI 020 PIC/S Site Master File for Plasma Warehouses

For GDP:

An Aide Mémoire on Inspection of Manufacturers and Wholesale Distributors for Compliance with GDP along with a Q&A for the PIC/S GDP Guide will be finalised by 2022.

Membership assessment:
With assessments and reassessments for membership put on hold for the last two years, these countries will be reassessed, which is the final step for membership: Chinese Taipei’s Food and Drug Administration (TFDA), Indonesia’s National Agency of Food and Drug Control (ADFC), New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe), and South Africa’s Health Products Regulatory Authority (SAHPRA).

The PIC/S Committee plans to meet face-to-face in Dublin, Ireland,  on 3 October 2022 in connection with PIC/S’ 50th Anniversary, which will be hosted by the Irish regulatory authority HPRA.


Source:

PIC/S: Work Plan 2022

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Previous
Next